Clozapine
FDA-approved product (tablet, oral), marketed as Clozapine, Clozaril, Fazaclo Odt and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Diazepines, oxazepines, thiazepines and oxepines
- FDA pharmacologic class
- Atypical Antipsychotic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clozapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
NCT00272584 · start 2001-06
Registered record
- Registry ID
- NCT00272584
- Conditions
- Psychosis, Schizophrenia
- Interventions
- Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2004-01
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsychosis, SchizophreniaInterventionRisperidonePhasePhase 4Registry statusCompletedCATIE- Schizophrenia Trial
NCT00014001 · start 2000-12
Registered record
- Registry ID
- NCT00014001
- Conditions
- Schizophrenia
- Interventions
- perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2004-12
- Enrolment
- 1,600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionperphenazine; olanzapine; quetiapine; risperidone +3 morePhasePhase 4Registry statusCompletedElectroconvulsive Therapy in Clozapine Refractory Schizophrenia
NCT00042224 · start 2000-12
Registered record
- Registry ID
- NCT00042224
- Conditions
- Schizophrenia
- Interventions
- Electroconvulsive Therapy (ECT); Clozapine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2008-07
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionElectroconvulsive Therapy (ECT); ClozapinePhasePhase 1 / Phase 2Registry statusCompletedStudy of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
NCT00004826 · start 1993-10
Registered record
- Registry ID
- NCT00004826
- Conditions
- Parkinson Disease
- Interventions
- clozapine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 1993-10
- Completion
- 1997-11
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson DiseaseInterventionclozapinePhaseNot applicableRegistry statusCompletedFazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
NCT00683891
Registered record
- Registry ID
- NCT00683891
- Conditions
- Weight Gain; Sialorrhea
- Interventions
- FazaClo (clozapine, USP) ODT
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWeight Gain; SialorrheaInterventionFazaClo (clozapine, USP) ODTPhaseNot recordedRegistry statusCompleted